Sector News

Pfizer vet Gutiérrez-Ramos takes the reins at Synlogic

May 21, 2015
Life sciences
José-Carlos Gutiérrez-Ramos, long Pfizer’s chief of biotherapeutic research, is heading back to the world of biotech, taking the top spot at Synlogic as the startup pursues a novel approach to drug development.
 
Gutiérrez-Ramos, who left Pfizer earlier this month, is stepping in about a year after Atlas Venture and New Enterprise Associates backed a $29.4 million funding round for Synlogic, helping the company get rolling with a proprietary approach to synthetic biology. Using technology licensed from MIT’s Timothy Lu and Boston University’s Jim Collins, Synlogic is working to engineer microbes that can be tuned to have specific therapeutic effects, focusing first on rare diseases.
 
And Gutiérrez-Ramos brings a long track record of successful translational research, overseeing more than 25 projects in his time at Pfizer and heading up development work at GlaxoSmithKline and Millennium Pharmaceuticals prior to that.
 
Now, with a chief executive in place, Synlogic is moving on from its stealthy platform development and unveiling its pipeline. Tapping its microbe-engineering engine, the biotech is developing two preclinical candidates for urea cycle disorders, which result from enzyme deficiencies, and phenylketonuria, a rare ailment caused by a gene defect.
 
“Synlogic has assembled an outstanding team of founders, scientists, collaborators and investors to make the potential of synthetic biology a reality for the treatment of human disease,” Gutiérrez-Ramos said in a statement. “I am thrilled to lead them in this fascinating journey to change the world by bringing the future of medicine forward.”
 
By Damian Garde
 

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach